On the driving processes of the Atlantic meridional overturning circulation

Because of its relevance for the global climate the Atlantic meridional overturning circulation (AMOC) has been a major research focus for many years. Yet the question of which physical mechanisms ultimately drive the AMOC, in the sense of providing its energy supply, remains a matter of controversy. Here we review both observational data and model results concerning the two main candidates: vertical mixing processes in the ocean's interior and wind-induced Ekman upwelling in the Southern Ocean. In distinction to the energy source we also discuss the role of surface heat and freshwater fluxes, which influence the volume transport of the meridional overturning circulation and shape its spatial circulation pattern without actually supplying energy to the overturning itself in steady state. We conclude that both wind-driven upwelling and vertical mixing are likely contributing to driving the observed circulation. To quantify their respective contributions, future research needs to address some open questions, which we outline.

El fenotipo "basal-her2" en el cáncer de mama: caracterización clínico-molecular e implicaciones terapéuticas

Clinically HER2+ (cHER2+) breast cancer (BC), as exclusively determined by immunohistochemistry of HER2 protein overexpression and/or fluorescence in situ hybridization of HER2 gene amplification, has been largely considered a single disease entity in terms of clinical outcome and in the susceptibility to the anti-HER2 monoclonal antibody trastuzumab (Herceptin). However, although the adjuvant/neoadjuvant use of the trastuzumab has been shown to significantly reduce recurrence risk when added to standard chemotherapy in women with early-stage cHER2+ BC, not all cases derive similar benefit from trastuzumab because a significant number of cHER2+ BC patients develop disease recurrence. Unfortunately, the identification of a robust clinical predictor of trastuzumab benefit, including HER2 itself, has proven challenging in the adjuvant/neoadjuvant setting. Thus, we suggest that a new generation of research needs to refine the prognostic taxonomy of cHER2+ BC and develop easy-to-use, clinicbased prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy ab initio. This study offered two hypotheses: 1.) HER2 overexpression can unexpectedly take place in a molecular background owned by basal-like BC (a commonly HER2-negative BC subtype which possesses many epithelial-mesenchymal transition (EMT) characteristics and exhibits robust cancer stem cell [CSC]-like features), thus generating a so-called basal/cHER2+ BC subtype; 2.) the basal/cHER2+ phenotype confers poor prognosis and delineates a subgroup of intrinsically aggressive cHER2+ BC with primary resistance to trastuzumab...